IL-1Ra: Its role in rheumatoid arthritis;IL-1Ra: Il suo ruolo nell'artrite reumatoide

Reumatismo

Volumn 56, Issue 1 SUPPL. 1, 2004, Pages 41-45

  Cutolo, Maurizio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Inflammation; Interleukin 1 receptor antagonist; Rheumatoid arthritis; Synovial tissue; Tumor necrosis factor alpha

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MATRIX METALLOPROTEINASE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

BONE DESTRUCTION; CYTOKINE PRODUCTION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ARTHRITIS, RHEUMATOID; CYTOKINES; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; SIALOGLYCOPROTEINS;

EID: 2342480448     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Straub R, Cutolo M. Impact of the hypothalamic-pituitary-adrenal/gonadal axes and the peripheral nervous system in rheumatoid arthritis: a systemic pathogenic view point. Arthritis Rheum 2001; 44: 493-507.
2. Cutolo M, Straub RH, Masi AT, Bijlsma JWJ, Lahita R, Bradlow HL. Altered Neuroendocrine Immune (NEI) Networks in Rheumatology. Ann NY Acad Sci 2002; 966: xiii.
3. Kalden JR. Biologic agents in the treatment of inflammatory rheumatic diseases. Curr Opin Rheumatol 1998; 10: 174-8.
4. Cutolo M. Macrophages as effectors of the immunoendocrinologic interactions in autoimmune rheumatic diseases. Ann N Y Acad Sci 1999; 876: 32-43.
5. Kremer JM. Emerging therapies for rheumatoid arthritis. Rheum Dis Clin North America 1998; 24: 3-8.
6. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999; 353: 1568-73.
7. Cutolo M, Bisso A, Sulli A, Felli L, Briata M, Pizzorni C, et al. Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from rheumatoid arthritis patients. J Rheumatol 2000; 27: 2551-7.
8. Cutolo M, Straub RH. Antiinflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001; 60: 729-35.
9. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. J Rheumatol 2000; 59: 841-9.
10. Dinarello CA. Biological basis for interleukin-1 in disease. Blood 1996; 87: 2095-147.
11. Clifton O, Bingham III. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J Rheumatol 2002; 29: 3-9.
12. Arend WP. Phisiology of cytokine pathways in rheumatoid arthritis. Arthritis Care Res 2001; 14: 397-440.
13. Dinarello CA. The IL-1 familty and inflammatory diseases. Clin Exp Rheumatol 2002; 20: 1-20.
14. Goldring SR. Bone and Joint destruction in rheumatodi arthritis: What is really happening? J Rheumatol 2002; 29: 44-8.
15. Van den Berg WB. Is there a rationale for combined TNF and IL-1 blocking in arthritis. Clin Exp Rheumatol 2002; 20: 21-5.
16. Dayer JM. Evidence for the biological modulation of IL-1 activity: the role of IL-1Ra. Clin Exp Rheumatol 2002; 20: 14-20.
17. Roux-Lombard P, Modoux C, Dayer JM. Production of interleukin-1 (IL-1) and a specific inhibitor during human monocyte-macrophage differentiation: influence of GM-CSF. Cytokine 1989; 1: 45-51.
18. Dinarello CA. The role of interleukin-1 receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000; 242: 732-4.
19. Cutolo M, Bresnihan B, Dayer JM. IL-1Ra as a new biological approach for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2002; 29: i.
20. Cauli A, Yanni G, Panayi GS. Interleukin-1, Interleukin-1 receptor antagonist and macrophage populations in rheumatoid arthritis synovial membrane. Br J Rheumatol 1997; 36: 935-40.
21. Bresnihan B. Anakinra as a new therapeutic option in rheumatoid arthritis. Clinical results and perspectives. Clin Exp Rheumatol 2002; 20: 32-4.
22. Cutolo M. Effects of DMARDS on IL-1Ra levels in rheumatoid arthritis: is there any evidence? Clin Exp Rheumatol 2002; 20: 26-31.